سعر ستازولا 100مجم 20 اقراص 2022

Stazola 100 mg (Chemipharm, Egypt), 20 tablets: cilostazol 100 mg, a phosphodiesterase 3 inhibitor with antiplatelet and vasodilating effects used for intermittent claudication.

• Reduction of symptoms of intermittent claudication, as shown by increased walking distancePopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (100 mg twice daily vs placebo): headache 34%, diarrhoea 19%, abnormal stools 15%, palpitation 10%, dizziness 10%, and peripheral oedema among others.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Heart failure of any severity (boxed warning: PDE3 inhibitors have decreased survival in class III-IV heart failure).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to cilostazol or any component of the tablets.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• May induce tachycardia, palpitation, tachyarrhythmia or hypotension; patients with ischaemic heart disease may be at risk of worsening angina or myocardial infarction.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Left ventricular outflow tract obstruction reported in patients with sigmoid-shaped septum; monitor for new systolic murmur or cardiac symptoms.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Thrombocytopenia or leukopenia progressing to agranulocytosis reported; monitor platelets and white cell counts periodically.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong or moderate CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, diltiazem, grapefruit juice)Increase cilostazol exposure; reduce cilostazol to 50 mg twice daily.DailyMed (U.S. National Library of Medicine)
• CYP2C19 inhibitors (ticlopidine, fluconazole, omeprazole)Increase exposure to cilostazol/active metabolite; reduce cilostazol to 50 mg twice daily.DailyMed (U.S. National Library of Medicine)

• Teratogenic in rats at doses above 5 times the maximum recommended human dose; no adequate and well-controlled studies in pregnant women.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Transfer into milk reported in rats; because of potential serious adverse reactions in nursing infants, discontinue nursing or discontinue cilostazol.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Cilostazol: Selective PDE3 inhibitor increasing cAMP; inhibits platelet aggregation and dilates arteries.